Patient Guide: A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 18 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT07005102
Status: 🟢 Enrolling Now
Condition: Non-Squamous Non-Small Cell Lung Cancer
Phase: PHASE2, PHASE3

Where You Can Participate

This study is available at 18 locations across the country.

Top locations include:
  • • Los Angeles, California
  • • Orange City, Florida
  • • West Des Moines, Iowa
  • • And 15 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer - Join Clinical Trial NCTNCT07005102

How to Join This Clinical Trial - NCTNCT07005102

Learn how to participate in this PHASE2, PHASE3 trial studying an investigational therapy for Non-Squamous Non-Small Cell Lung Cancer. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Non-Squamous Non-Small Cell Lung Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Non-Squamous Non-Small Cell Lung Cancer
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2, PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT07005102 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 18 locations. Find a study site near you:

Clinical Research Site

Los Angeles, California 90033 - United States

Status: RECRUITING

Clinical Research Site

Orange City, Florida 32763 - United States

Status: RECRUITING

Clinical Research Site

West Des Moines, Iowa 50266 - United States

Status: RECRUITING

Clinical Research Site

Lincoln, Nebraska 68506 - United States

Status: RECRUITING

Clinical Research Site

Reno, Nevada 89502 - United States

Status: RECRUITING

Clinical Research Site

Woodville, South Australia 5011 - Australia

Status: RECRUITING

Clinical Research Site

Heidelberg, Victoria 3084 - Australia

Status: RECRUITING

Clinical Research Site

Murdoch, Western Australia 6150 - Australia

Status: RECRUITING

Clinical Research Site

Ramat Gan, Tel Aviv 5265601 - Israel

Status: RECRUITING

Clinical Research Site

Haifa, 3525408 - Israel

Status: RECRUITING

And 8 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2, PHASE3 clinical trial for Non-Squamous Non-Small Cell Lung Cancer:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships